ALFA Finder| Metric | Q4 FY26 | Q3 FY26 | Q4 FY25 |
|---|---|---|---|
| Revenue from operations | 578.6 | 611.6 | 480.5 |
| Other income | 6.0 | 5.1 | 16.1 |
| Total income | 584.6 | 616.7 | 496.6 |
| Profit before exceptional items & tax | 59.2 | 45.1 | 84.2 |
| Exceptional items | -1.1 | 1.5 | -5.7 |
| Profit before tax | 58.1 | 46.5 | 78.5 |
| Net profit | 44.9 | 32.6 | 58.2 |
| Operating margin | 9.9% | 7.5% | 15.8% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | -22.90% |
|---|---|
| Net profit, quarter on quarter | +37.70% |
| Revenue, year on year | +20.40% |
BSE results filing, NSE: ASTRAZEN. Figures extracted from the filing.
AstraZeneca Pharma India Ltd: key numbers
- Share price
- ₹6,507.00
- Market cap
- ₹16,268 Cr
- Revenue (annual)
- ₹2,276 Cr
- Net profit (annual)
- ₹187.5 Cr
- P/E (TTM)
- 91.5×Sector 43.8×
- Promoter holding
- 75.00%+0.00% QoQ
- FII holding
- 2.64%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from AstraZeneca Pharma India Ltd
All →AstraZeneca Pharma India Product Launch
AstraZeneca Pharma India will launch Datverzo, Datopotamab Deruxtecan, in India in November 2026. The drug holds DCGI import and market permission for HR-positive, HER2-negative breast cancer.
AstraZeneca Pharma India Legal & Regulatory
AstraZeneca Pharma India may receive a revised Bengaluru civic demand for improvement charges. Charges are likely capped at Rs.70.8 million plus interest, and Rs.156.1 million is already provided.
- Value
- ₹7.08 Cr
AstraZeneca Pharma India Results Update
AstraZeneca Pharma India reported 30% growth in Q2 results, with three new regulatory approvals. It also announced MoUs with two state governments.
AstraZeneca Pharma India Q2 FY27 Results: Net Profit ₹62.3 Cr, Up 14.9% YoY
AstraZeneca Pharma India Ltd reported revenue from operations of ₹729.1 Cr (+30.4% YoY) and net profit of ₹62.3 Cr (+14.9% YoY) for Q2 FY27.
- Key figure
- Net profit ₹62.3 Cr · +14.9% YoY
AstraZeneca Pharma India Legal & Regulatory
Delhi High Court directed NPPA to refrain from coercive steps on Rs.151.20 Crore alleged Symbicort Turbuhaler overcharging. Next hearing is January 11, 2027.
- Value
- ₹151.2 Cr
AstraZeneca Pharma India Other Announcement
AstraZeneca Pharma India filed its quarterly shareholding pattern for the period ended 30 September 2026. Promoter and promoter group hold 75% of total equity.